associated risk factors. The recent trials on blood pressure control at lower levels of systolic blood pressure, including the Systolic Blood Pressure Intervention Trial (SPRINT)11 and Heart Outcomes Prevention Evaluation-3 (HOPE-3) trial,12 have also brought attention to the difference between a population health perspective on the quantification of risks and the clinical question of risk reversibility. The CRA framework provides an important insight into the role of different risks in contributing to levels of population health but does not necessarily provide all the information necessary to guide individual clinical decision making.
